Treatment for acute myeloid leukemia (AML) usually happens in two phases: induction therapy to clear the leukemia from the blood and marrow, then consolidation to stop it coming back. What drugs a patient gets, and whether they need a stem cell transplant, depends on the genetics of the leukemia, the patient’s age and fitness, and how well the first round works. Below I go through how those decisions are made and where AML treatment has moved in recent years.
What AML Is and Why It Needs Urgent Treatment
AML is a cancer of the blood-forming cells in the bone marrow. An early myeloid cell picks up genetic damage and starts making copies of itself that never mature. These immature cells, called myeloblasts, pile up in the marrow and spill into the bloodstream.
As the blasts crowd the marrow, normal blood cell development is squeezed out. The result is anemia, low platelets, and too few working neutrophils. Without treatment, AML can become life-threatening within weeks, which is why we usually start therapy quickly after diagnosis.
AML is not one disease. The World Health Organization (WHO) classification sorts it into subtypes based on genetic, molecular, and chromosomal features. Common mutations include FLT3, NPM1, CEBPA, IDH1, and IDH2. Many of these now point to specific drugs, so testing for them has become central to treatment planning.
How AML Is Diagnosed Before Treatment Starts
Most patients come in with symptoms of failing bone marrow function: tiredness and breathlessness from anemia, easy bruising or nosebleeds from low platelets, and fevers or infections that keep coming back. A complete blood count often looks abnormal, and blasts may be visible on the blood smear.
A bone marrow aspirate and biopsy confirms the diagnosis. Traditionally, AML is defined by at least 20% blasts in the marrow or blood. Certain defining genetic changes allow the diagnosis at a lower blast count. The marrow sample then goes through several tests:
- Morphology: looking at the cells under the microscope.
- Flow cytometry: identifying surface markers to confirm the cells are myeloid.
- Cytogenetics: checking chromosomes for translocations, deletions, or extra copies.
- Molecular testing: looking for mutations such as FLT3, NPM1, and IDH1/2, often with a next-generation sequencing panel.
Together, these results place the patient in a risk group: favorable, intermediate, or adverse. The risk group is one of the strongest factors in the treatment plan.
Standard AML Leukemia Treatment: Induction and Consolidation
For fit patients, the classic induction regimen is “7+3”. Cytarabine runs as a continuous infusion for seven days, with an anthracycline such as daunorubicin or idarubicin given on the first three days. The goal is complete remission: blasts below 5% in the marrow and blood counts starting to recover.
Induction is hard on the body. Counts fall very low for a few weeks, so patients usually stay in hospital with transfusion support and quick treatment of any infection. A repeat marrow test around the time counts recover shows whether remission has been reached.
Remission does not mean cure. Leukemia cells too few to see under the microscope usually remain, so consolidation follows. In favorable-risk disease this is often several cycles of higher-dose cytarabine. In intermediate- or adverse-risk disease, many patients go on to an allogeneic stem cell transplant from a matched donor if they are well enough.
| Phase | Aim | Typical approach |
|---|---|---|
| Induction | Clear blasts and reach complete remission | “7+3” chemotherapy, often with a targeted drug added |
| Consolidation | Destroy remaining leukemia cells | Higher-dose cytarabine cycles or allogeneic stem cell transplant |
| Maintenance (selected cases) | Lower the risk of relapse | Oral or low-intensity therapy in specific settings |
| Relapsed or refractory | Regain control of the disease | Targeted drugs, salvage chemotherapy, clinical trials, transplant |
Targeted Therapies: Matching Drugs to Mutations
The biggest shift in AML care has come from drugs aimed at specific genetic changes. This is where testing at diagnosis matters most, because the result can change the plan in the first week.
- FLT3 inhibitors: midostaurin can be added to induction chemotherapy for FLT3-mutated AML. Gilteritinib is used in relapsed or refractory FLT3-mutated disease.
- IDH inhibitors: ivosidenib targets IDH1 mutations and enasidenib targets IDH2 mutations. Both are oral drugs.
- Gemtuzumab ozogamicin: an antibody linked to a toxin. It targets CD33, a marker found on most AML cells.
- Venetoclax: a BCL-2 inhibitor. Combined with azacitidine or decitabine, it has become a standard option for older adults or people who cannot tolerate intensive chemotherapy.
One subtype deserves its own mention. Acute promyelocytic leukemia (APL), defined by the t(15;17) translocation, is treated with all-trans retinoic acid (ATRA) and arsenic trioxide rather than standard chemotherapy. It can cause dangerous bleeding early on, so it is treated as an emergency, but it is one of the most curable forms of AML.
Treating Older or Less Fit Patients
AML is most common in older adults, and many cannot safely receive intensive “7+3” induction. For these patients, lower-intensity regimens such as venetoclax with a hypomethylating agent (azacitidine or decitabine) are often the preferred choice. These can frequently be given largely as an outpatient.
In my practice, the conversation with older patients focuses on their goals as much as the blood counts. Some want the most aggressive route to remission. Others put more weight on time at home and quality of life. Both are reasonable, and good supportive care, including transfusions, infection prevention, and symptom control, matters for everyone.
Advancing AML Treatment: Where Research Is Heading
Several areas of research are shaping the next generation of AML care. Broader overviews of AML leukemia treatment and other leukemia strategies place these in context, but the main themes are:
- Measurable residual disease (MRD) testing: sensitive flow cytometry or molecular tests that find leukemia cells below the level visible under the microscope, helping decide who needs a transplant.
- Immunotherapy: CAR T-cell therapy and bispecific antibodies are being studied in relapsed AML. Finding a target that spares healthy blood stem cells has been harder than in lymphoid leukemias.
- The bone marrow microenvironment: the supporting cells around the leukemia may shield it from drugs, making that environment a possible treatment target.
- Serial sequencing: repeating genetic tests over time to track how the leukemia evolves and spot resistance early.
Clinical trials remain an important option at every stage, especially for adverse-risk or relapsed disease. You can find more foundational material in our leukemia guide.
Key Takeaways
- AML is an aggressive cancer of immature myeloid cells, and treatment usually starts soon after diagnosis.
- Genetic and molecular testing of the marrow sets the risk group and often decides which drugs are used.
- Fit patients typically receive “7+3” induction followed by consolidation chemotherapy or a stem cell transplant.
- Targeted agents for FLT3, IDH1, IDH2, CD33, and BCL-2 have widened the options, especially for older adults.
- MRD testing, immunotherapy, and research on the marrow microenvironment are the main areas of progress.
Frequently Asked Questions
How long does AML treatment take?
Induction usually involves a hospital stay of around four to six weeks while counts recover. Consolidation then continues over several months. If a stem cell transplant is planned, the full course, including recovery, can extend well beyond a year.
Can AML be cured?
Yes, some patients are cured, particularly younger people with favorable-risk genetics and those who respond well to intensive therapy or transplant. Outcomes vary widely with age, fitness, and the genetic profile of the leukemia. Your hematologist can explain what your own results suggest.
Why do I need to wait for genetic test results?
Some results, such as FLT3 status, determine whether a targeted drug should be added to induction. Rapid tests usually return within days. Unless the situation is an emergency, a short wait lets the team choose the most effective treatment from the start.
What are the main side effects of induction chemotherapy?
Expect very low blood counts, a high risk of infection, fatigue, mouth sores, nausea, and hair loss. Most patients need blood and platelet transfusions. The team watches closely for fever, which needs prompt antibiotics.
Who needs a stem cell transplant for AML?
A transplant is generally considered for intermediate- or adverse-risk AML in remission, for persistent MRD, and after relapse. It is only offered to patients fit enough to tolerate it who have a suitable donor. Favorable-risk patients often do well with chemotherapy alone.
